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ABSTRACT
Introduction: Cefazolin is commonly used to
treat complicated skin and soft tissue infections
(cSSTI) caused by methicillin-susceptible
Staphylococcus aureus (MSSA) and
Enterobacteriaceae. We aimed to determine
the variability of cefazolin exposure in
interstitial fluid (ISF) of tissue and evaluate its
dosing recommendations.
Methods: Population pharmacokinetics were
performed to co-model serum and ISF
concentration data from six patients enrolled in
a previous in vivo microdialysis study. A 5,000
patient Monte Carlo simulation was then
conducted for 1 and 2 g every 8 h (q8h) regimens
to calculate the penetration ratio and probability
of target attainment (PTA) at 30% and 50% of the
dosing interval that free drug concentrations
remain above the minimum inhibitory
concentration (fT[MIC) in ISF of tissue.
Results: A three-compartment model, with one
of the compartments representing ISF
concentrations, fits the data best. The final
model resulted in the mean ± SD parameter
values: Clearance = 3.8 ± 2.1 L/h, volume of
distribution in central compartment = 8.6 ±
6.4 L and volume of distribution in ISF =
36.6 ± 17.9 L. The mean ± SD and median
penetration ratios were 1.36 ± 4.57 and 0.80,
respectively. At the MIC90 for MSSA of 1 mg/L,
PTAs for the 1 g q8h dose in ISF were 96% and 91%
for 30% and 50% fT[MIC targets, respectively,
which decreased to 87% and 71% at 2 mg/L. For
the same respective targets, a 2 g q8h dosing
regimen increased PTA to 96% and 91% at 2 mg/L.
Conclusion: Cefazolin penetration into the ISF
of a lower limb infection varied across this
simulated patient population. Based on these
data, a 1 g q8h regimen should be sufficient to
obtain 30% fT[MIC exposure against most
MSSA causing cSSTI. However, a 2 g q8h dose is
required to obtain 50% fT[MIC
pharmacodynamic targets at the current
breakpoint for Enterobacteriaceae (2 mg/L).
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(MSSA) is one of the most common causes of
complicated skin and soft tissue infection
(cSSTI) [1]. Among deeper cSSTI and those
located in the lower limb of diabetic patients,
Gram-negative bacilli, Escherichia coli, Klebsiella
pneumoniae, and Proteus species, are also
commonly isolated [1, 2]. Based on this
epidemiology, intravenous cefazolin has often
been used to treat cSSTI for organisms proven
susceptible in the hospital settings. However,
dosing recommendations vary based on source
and organism. Current US labeling for cefazolin
includes a variety of dosing regimens as low as
250 mg every 8 h (q8h) up to 2 g q8h [3].
Susceptibility breakpoints also vary for
cefazolin; the U.S. Food and Drug
Administration (FDA), the European
Committee on Antimicrobial Susceptibility
Testing (EUCAST), or the Clinical Laboratory
Standards Institute (CLSI) breakpoints have not
taken cefazolin tissue exposure into account
when selecting susceptibility thresholds. The
FDA susceptibility breakpoint for cefazolin
against S. aureus has remained B16 mg/L for
decades [3], while cefazolin minimum
concentration at which 50% (MIC50) and 90%
(MIC90) of the isolates were inhibited against
MSSA was recently reported as 0.5 mg/L and
1 mg/L, respectively [4]. EUCAST has not
published a cefazolin susceptibility breakpoint
for Enterobacteriaceae and relies on the
cefoxitin disc test for determining universal
susceptibility to first-generation
cephalosporins. The CLSI uses a similar
definition for S. aureus, and more recently has
modified its susceptibility breakpoint for
Enterobacteriaceae twice since 2010. This was
prompted by publications reporting treatment
failures from cephalosporins in infections
caused by Enterobacteriaceae that were
previously categorized as susceptible [5–7].
Initially, it was lowered from B8 mg/L to
B1 mg/L in 2010 with the advent of in vitro
susceptibility, pharmacodynamic, and clinical
outcome data. It was then readjusted to B2 mg/
L in 2011 with the recommendation of a 2 g
q8h dosing regimen, so that it could still be a
viable option for Enterobacteriaceae without
intrinsic chromosomal cephalosporinases [7].
In an effort to quantify drug concentrations
in the interstitial fluid (ISF) of tissue to
determine if appropriate pharmacodynamic
targets are achieved at the site of infection,
our group previously reported ISF exposure of
cefazolin in seven chronic lower extremity
wound infections utilizing in vivo
microdialysis techniques [8, 9]. The non-
compartmental pharmacokinetic analysis from
the study showed the mean and median tissue
penetration ratios [ISF/serum free drug area
under the curve (fAUC)] of 1.06 and 0.88 with
a wide range of 0.19–1.68. The percent of the
dosing interval that free drug concentrations
remained above the MIC (%fT[MIC) in the
sampled ISF was 100% at an MIC of 1 mg/L for
five out of six patients who received 1 g q8h
dose during the study.
In this study, we aimed to describe the
population pharmacokinetics of cefazolin in
both serum and ISF utilizing the data from the
aforementioned study [8]. We used this model
to simulate the potential variability in
penetration into ISF of tissue and to compare
the likelihood of achieving targeted drug
exposure (i.e., fT[MIC) in the ISF
compartment between 1 g versus 2 g q8h
regimens.
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METHODS
Patient Population and Setting
Included patients were those from the
aforementioned in vivo microdialysis study,
which was an open-label pharmacokinetic study
at Hartford Hospital, Hartford, CT, USA [8].
Inclusion criteria were hospitalized adult patients
(age C18 years) with lower extremity wound
infections requiring surgical debridement and
defined as mild or moderate by the Infectious
Diseases Society of America oras grade 2or3 by the
InternationalConsensusontheDiabeticFoot [10].
Patients with hypersensitivity to anesthetics
(lidocaine or lidocaine derivatives), pregnancy or
breastfeeding, no palpable pedal pulses, likelihood
to require multiple procedures during the study,
participation in another study of an
investigational drug or device within the
preceding 30 days, and patients with renal
dysfunction, defined as an estimated creatinine
clearance (CrCl) less than 50 mL/min, were
excluded. The analysis in this article is based on a
previously conducted study and does not involve
any new studies with human or animal subjects
performed by any of the authors.
Drug Administration
All patients received intravenous cefazolin over
30 or 60 min for their lower extremity wound
infections via a peripheral catheter placed in the
arm or a peripherally inserted central catheter
(PICC). All patients included in this analysis
received 1 g q8h dosing.
Sampling and Determination of Cefazolin
Concentrations
Venous blood samples (7–9 per patient) were
collected at various time points from a
peripheral intravenous catheter or PICC after a
minimum of four doses (i.e., steady state).
Sampling time points included immediately
prior to and after the infusion, several points
hourly after the infusion, and then just prior to
the next dose. Dialysate samples of *120 lL
were obtained from the microdialysis catheters
at each of the corresponding blood sample time
points. Microdialysis catheters were calibrated
for each patient after sampling by using the
in vivo retrodialysis technique [11]. Cefazolin
concentrations in serum and ISF were
quantified by a validated high-performance
liquid chromatography assay [12].
Population Pharmacokinetics
Cefazolin serum and ISF concentrations were
co-modeled by the non-parametric adaptive
grid (NPAG) with adaptive gamma algorithm
available in the Pmetrics package for R (LAPK,
Los Angeles, CA, USA) [13]. A total of 53 serum
and 53 ISF concentrations from six patients
were used, and individual concentrations were
weighted by the reciprocal of assay variance
multiplied by gamma. Weighting based on
interday assay variance was employed using a
plot of the assay standard deviation (SD) versus
measured cefazolin concentrations, which was
best described by the equations: SDserum =
c(0.0071 ? 0.0449 9 C1) and SDISF = c(0.0002
? 0.0560 9 C2), where C1 and C2 are cefazolin
concentrations in serum and ISF, respectively,
and c was identified as 3.76. Mean values were
used as the measure of central tendency for
population parameter estimates. Bayesian
estimates were obtained for each patient using
the population-of-one utility within Pmetrics.
Both two- and three-compartment models
were explored, with one of the compartments
being the sampled ISF. Multiple models were
evaluated and discriminated employing the
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Akaike Information Criterion (AIC) [14], which
is a function of the likelihood of the model,
penalized by the number of parameters in the
model, bias, imprecision, and by visual
inspection of the observed versus predictive
concentration plots. The mean weighted error
was used as the estimate of bias. The bias-
adjusted mean weighted squared error was
employed as the estimate of imprecision.
Linear regression (Sigma Plot Version 12.5,
Systat, Chicago, IL, USA) was used to
characterize the relationship between
pharmacokinetic parameters (CL, clearance
from central compartment; Vc, volume of
central compartment and VISF, volume of
sampled ISF compartment) and patient
covariates (CrCl calculated by Cockcroft–Gault
equation [15, 16], TBW, total body weight and
BMI, body mass index). Covariates that were
statistically significantly correlated were then
incorporated back into the population model
and tested for model superiority.
Monte Carlo Simulations
A 5,000 patient semi-parametric Monte Carlo
Simulation (Pmetrics) [13] was conducted to
simulate steady-state concentrations of
cefazolin 1 g and 2 g in both serum and ISF.
Pmetrics’ semi-parametric simulator uses the
non-parametric ‘‘support points’’ from the final
population model, each a vector of one value
for each parameter in the model and the
associated probability of that set of parameter
values, to serve as the mean of one multivariate
normal distribution. The weight of each
multivariate distribution is equal to the
probability of the point. The overall
population covariance matrix is divided by the
number of support points and applied to
each distribution for sampling. Cefazolin
concentrations in serum and tissue for seven
doses of each regimen were simulated every
15 min after the last dose. A fraction unbound
of 15% (i.e., 85% protein binding) was applied
to correct all serum concentrations to free drug
concentrations. This fraction unbound estimate
was consistent across the six patients, as well as
within each patient across the dosing interval
[8]. ISF concentrations were assumed to be
unbound during calculation of AUC and
fT[MIC in ISF. The AUC for a dosing interval
of 8 h (AUC0–8) at steady state was estimated in
serum and ISF after simulation to calculate the
penetration into ISF as AUCISF/fAUCserum. The
probability of target attainment (PTA) was
calculated using a priori pharmacodynamic
targets defined as 30%, 50%, and 100%
fT[MIC in serum and ISF.
RESULTS
Patient Characteristics
A total of six patients were included in this
analysis. Five out of six patients were male and
their age ranged from 35 to 83 years with a
mean ± SD of 55 ± 17 years (Table 1). Five out
of six patients had diabetes (one with type I,
four patients with type II). One patient did not
have diabetes but had significant neuropathy,
which contributed to the foot infection. None
of the six patients had a history of peripheral
vascular disease, and all had pedal pulses from
?1 to ?3 at the time of sampling. Surgical
interventions involved were amputation or
debridement of the infected tissue and/or
bone. Sampling occurred after the surgical
intervention for five out of the six patients
except in one patient, which occurred a day
prior to surgery.
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Population Pharmacokinetics
A three-compartment base model fit the data
better than a two-compartment model based on
our discrimination criteria. Although linear
regression identified CrCl as the only patient
covariate that was significantly correlated with
CL (r2 = 0.822, P = 0.005) and no patient
covariates were significantly correlated with Vc
or VISF, incorporation of CrCl back into the base
model did not improve the AIC. Therefore, the
simpler non-covariate three-compartment
model was selected. The final model AIC and
log-likelihood were 453.3 and -218.8,
respectively. Final population pharmacokinetic
parameters obtained from the analysis are listed
in Table 2.
Figure 1 demonstrates the observed versus
(Fig. 1a) population predicted and (Fig. 1b)
individual predicted maximum posterior
(MAP) concentrations in serum. The
population predicted estimates were
reasonable for a patient population with
variable pharmacokinetics with r2, bias, and
imprecision values of 0.64, 12.7, and 920,
respectively (Fig. 1a). MAP Bayesian
concentration plot in serum was excellent
with r2, bias, imprecision values of 0.98,
-0.373, and 7.6, respectively (Fig. 1b). In ISF,
the observed versus population predicted r2,
bias, and imprecision were 0.198, 20.1, and
1,394 (Fig. 2a), and the corresponding values for
the observed versus individual MAP Bayesian
plot were 0.887, -1.17, and 21.3, respectively
(Fig. 2b).
The mean ± SD and median penetration
ratios for the six included patients based on
their individual Bayesian parameter estimates
were 0.90 ± 0.48 and 0.72, respectively.
Monte Carlo Simulation
Parameter estimates from the Pmetrics semi-
parametric simulator recapitulated the mean,
SD, and median estimates of the original model.
The mean ± SD and median penetration ratios
for 5,000 simulated patients were 1.36 ± 4.57
and 0.80, respectively. The 5th and 95th
percentiles for simulated penetration into ISF
were 0.15 and 2.74, respectively. PTA results for
serum and ISF exposures of 30%, 50%, and
100% fT[MIC are provided in Table 3.
DISCUSSION
The previously published cefazolin in vivo
microdialysis study by our group evaluated ISF
concentrations of intravenously administered
Table 2 Final parameter estimates from the population pharmacokinetic model





Mean 3.8 8.6 1.6 4.0 1.4 2.0 36.6
SD 2.1 6.4 1.6 1.6 1.3 1.5 17.9
%CV 55.2 74.6 103.7 40.9 94.2 72.2 48.8
Median 2.8 6.5 2.1 5.0 0.9 0.9 41.0
CL Clearance from central compartment, K12 transfer rate constant from central to peripheral compartment, K13 transfer
rate constant from central to the sampled interstitial ﬂuid of tissue compartment, K21 transfer rate constant from peripheral
to central compartments, K31 transfer rate constant from the sampled interstitial ﬂuid of tissue compartment to central
compartment, SD standard deviation, %CV coefﬁcient of variation, Vc volume of the central compartment, VISF volume of
the sampled interstitial ﬂuid of tissue compartment
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cefazolin for the treatment of cSSTI [8]. The
primary goal of the current study was to
describe the population pharmacokinetics
using the same serum and ISF concentration
data to assess variability in ISF penetration and
the likelihood of achieving fT[MIC in the ISF
compartment between 1 g and 2 g q8h
regimens.
A three-compartment model best described
the pharmacokinetics of cefazolin in our
population with normal renal function. The
resultant CL of 3.78 ± 2.09 L/h from our
population pharmacokinetic model was
concordant with the values from the non-
compartmental analysis, 3.72 ± 2.16 L/h [8].
Cefazolin CL in this population was also
similar to most other reported values. van
Kralingen and colleagues [17] have reported
CL of 4.2 ± 0.1 L/h in patients with
average ± SD age of 44 ± 11 years, TBW of
151 ± 35 kg, and BMI of 51 ± 10 kg/m2 after a
single prophylactic dose of 2 g prior to bariatric
surgery. They also observed CL had a significant
negative correlation with age, but not with
Fig. 1 Observed versus (a) population predicted and
(b) individual predicted maximum posterior Bayesian
cefazolin concentrations (mg/L) in serum. CI Conﬁdence
interval, Inter Intercept
Fig. 2 Observed versus (a) population predicted and
(b) individual predicted maximum posterior Bayesian
cefazolin concentrations (mg/L) in interstitial ﬂuid of
tissue. CI Conﬁdence interval, Inter Intercept
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body weight. Douglas and colleagues [18]
reported median CL of 3.01 L/h (interquartile
range: 1.73–3.94 L/h) after a single 2 g cefazolin
in patients undergoing abdominal aortic
aneurysm open repair surgery. A tissue
penetration study of cefazolin in morbidly
obese versus non-obese patients reported a CL
of approximately 23 L/h [19]; however, this
estimate was based on unbound cefazolin
concentrations and is therefore not directly
comparable. Nonetheless, this unbound CL
estimate is feasible because cefazolin is highly
protein bound; protein binding in our six
patients was 85%.
The observed mean ± SD and median
penetration ratios from our six patients using
their individual Bayesian parameter estimates
were 0.90 ± 0.48 and 0.72 (range 0.61–1.87),
respectively; these values were similar to the
original observed penetration ratios based on
trapezoidal rule: 1.21 ± 0.67 and 0.90 (range
0.7–2.68), respectively [8]. The Monte Carlo
simulation incorporates variability between
patients in the pharmacokinetic estimates, and
as a result, the mean ± SD and median
simulated penetration ratios were 1.36 ± 4.57
and 0.80, respectively. These penetration ratio
are comparable with the values observed by Brill
Table 3 Probability of achieving pharmacodynamic exposure thresholds in serum (a) and interstitial ﬂuid of tissue (b) for
cefazolin 1 g and 2 g q8h dosing regimens from 5,000 patient Monte Carlo simulation
MIC (mg/L) 1 g q8h 2 g q8h
30% fT > MIC 50% fT > MIC 100% fT > MIC 30% fT > MIC 50% fT > MIC 100% fT > MIC
(a) Serum
0.125 1.00 0.99 0.96 1.00 0.99 0.96
0.25 0.99 0.99 0.93 1.00 0.99 0.96
0.5 0.99 0.98 0.84 0.99 0.99 0.93
1 0.99 0.97 0.66 0.99 0.98 0.84
2 0.98 0.79 0.41 0.99 0.97 0.66
4 0.77 0.61 0.08 0.98 0.79 0.41
8 0.33 0.09 0.01 0.77 0.61 0.08
16 0.03 0.01 0.00 0.34 0.09 0.01
(b) Interstitial ﬂuid of tissue
0.125 0.99 0.98 0.93 0.99 0.99 0.95
0.25 0.99 0.97 0.89 0.99 0.98 0.93
0.5 0.98 0.96 0.77 0.99 0.97 0.89
1 0.96 0.91 0.58 0.98 0.96 0.77
2 0.87 0.71 0.39 0.96 0.91 0.58
4 0.58 0.45 0.20 0.87 0.71 0.39
8 0.29 0.18 0.08 0.58 0.45 0.20
16 0.10 0.07 0.03 0.29 0.18 0.08
fT[MIC Free time above MIC, q8h every 8 h
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and colleagues [19] who compared population
pharmacokinetics of surgical prophylactic dose
of cefazolin 2 g in both morbidly obese (BMI
47 ± 6 kg/m2) and non-obese (BMI 28 ±
3 kg/m2) patients using in vivo microdialysis.
Their observed fAUCISF/AUCserum was 0.70
(range 0.68–0.83) in morbidly obese and 1.02
(range 0.85–1.41) in non-obese patients. The
aforementioned study by Douglas and
colleagues [18] reported 85% penetration
(range 78–106%). Taken collectively, these
data consistently suggest that there is the
potential for a wide range in the estimate for
cefazolin penetration into ISF, which may
unpredictably be greater than or less than
exposures in serum.
While penetration ratio was calculated to
display the relative exposure of cefazolin in ISF
of tissue versus in serum, the pharmacodynamic
target of interest for the efficacy of cefazolin in
ISF remains fT[MIC [20–22]. Although the
cefazolin target fT[MIC in ISF needed for
efficacy against MSSA and Enterobacteriaceae
are unknown, 30% for MSSA [22–24] and 50%
for Enterobacteriaceae [22, 25, 26] were
employed as these are targets required in
blood. A target of 100% fT[MIC was also
included for comparison. Consistent with
current breakpoints, where applicable, PTAs
for cefazolin 1 g q8h in serum were high at
MICs of 1 mg/L and 2 mg/L (Table 3a).
However, analysis of exposure probabilities in
tissue revealed much lower PTA results. At the
MIC90 for MSSA of 1 mg/L, the PTA for a 1 g q8h
dose in ISF was 96% using the 30% fT[MIC
target (Table 3b). At an MIC of 2 mg/L,
the current-susceptible breakpoint for
Enterobacteriaceae, a 1 g q8h regimen
obtained a PTA of 71% for 50% fT[MIC
(Table 3b), but a 2 g q8h dosing regimen
increased the PTA to 91% for the same target
(Table 3b). PTAs for 50% fT[MIC in tissue from
our study for the 2 g dose are comparable with
PTAs reported by Brill and colleagues [19]: 96%
and 91% (Table 3b) versus 100% and 96% at
MIC of 1 mg/L and 2 mg/L, respectively.
The primary limitation of our study is its
small sample size. Only six patients, all with
normal renal function, were included in the
final model. Despite the knowledge of
correlation between cefazolin CL and renal
dysfunction, the small number of patients
with normal renal function in our study made
it challenging to improve the model by adding
this covariate. Additionally, while morbid
obesity can be an important factor in
determining cefazolin pharmacokinetics [19],
our small sample size did not allow us to use
weight as a covariate and future studies are
needed to further define optimal cefazolin
dosing in this population. Nonetheless, this is
the first study to address variability in cefazolin
penetration among patients with chronic
wound infections. Our results are also
consistent with the current recommended
dosing regimen for treatment of
Enterobacteriaceae based on the CLSI
breakpoint (i.e., 2 g q8h), as well as the dosage
typically utilized for S. aureus skin and soft
tissue infections (i.e., 1 g q8h).
CONCLUSION
Cefazolin penetration into the ISF of a lower
limb infection varied across this simulated
patient population. Cefazolin 1 g q8h fT[MIC
exposures in serum were high at MICs of 1 mg/L
and 2 mg/L. Based on the tissue ISF exposure in
this mixed obese and non-obese population
with normal renal function, 1 g q8h dose
regimen should be sufficient to achieve 30%
fT[MIC target against most MSSA causing
cSSTI. However, for Enterobacteriaceae with
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MIC of 2 mg/L, PTAs for the established 50%
fT[MIC target were not optimal with 1 g q8h
dose. At least 2 g q8h dose is required to achieve
PTA of C80% when treating cSSTI caused by
susceptible Enterobacteriaceae (MIC B 2 mg/L).
ACKNOWLEDGMENTS
This work was supported internally by the
Center for Anti-Infective Research and
Development, Hartford Hospital, Hartford,
CT, USA. We acknowledge Amira Bhalodi,
PharmD and Seth Housman, PharmD for
collection of the original cefazolin serum
and tissue concentration data, and Michael
Neely, MD for his guidance during the
population pharmacokinetic analysis and
Monte Carlo simulation. The contents of
this article were presented as a poster at the
54th Interscience Conference on
Antimicrobial Agents and Chemotherapy in
Washington, DC, USA. All named authors
meet the ICMJE criteria for authorship for
this manuscript, take responsibility for the
integrity of the work as a whole, and have
given final approval for the version to be
published.
Conflict of interest. Wonhee So, Joseph L.
Kuti, and David P. Nicolau declare that they
have no conflict of interest.
Compliance with ethics guidelines. The
analysis in this article is based on a previously
conducted study and does not involve any new
studies with human or animal subjects
performed by any of the authors.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution Noncommercial License which
permits any noncommercial use, distribution,
and reproduction in any medium, provided
the original author(s) and the source are
credited.
REFERENCES
1. Zervos MJ, Freeman K, Vo L, et al. Epidemiology
and outcomes of complicated skin and soft tissue
infections in hospitalized patients. J Clin Microbiol.
2012;50(2):238–45.
2. Garau J, Ostermann H, Medina J, et al. Current
management of patients hospitalized with
complicated skin and soft tissue infections across
Europe (2010–2011): assessment of clinical practice
patterns and real-life effectiveness of antibiotics
from the REACH study. Clin Microbiol Infect.
2013;19(9):E377–85.
3. Cefazolin package insert. http://www.
sagentpharma.com/Products/Cefazolin/Catalog/
Cefazolin_PI1.pdf?PHPSESSID=22da06f6533ba6c35
76d3c28d8b41882. Accessed June 16, 2014.
4. Housman ST, Sutherland CA, Nicolau DP.
Pharmacodynamic profile of commonly
utilisedparenteral therapies against methicillin-
susceptible/resistant Staphylococcus aureus from US
hospitals. (Abstract No. eP178). The 24th European
Congress of Clinical Microbiology and Infectious
Diseases, Barcelona, Spain, May 2014.
5. Paterson DL, Ko WC, Von Gottberg A, et al.
Outcome of cephalosporin treatment for serious
infections due to apparently susceptible organisms
producing extended-spectrum b-lactamases:
implications for the clinical microbiology
laboratory. J Clin Microbiol. 2001;39(6):2206–12.
6. Clinical and Laboratory Standards Institute. 7th ed.
M100 S20–S23. CLSI, Wayne, PA, USA; 2012.
7. Turnidge JD. On behalf of the subcommittee on
antimicrobial susceptibility testing of the Clinical
and Laboratory Standards Institute. Cefazolin and
Enterobacteriaceae: rationale for revised
susceptibility testing breakpoints. Clin Infect Dis.
2011;52(7):917–24.
8. Bhalodi AA, Housman ST, Shepard A, Nugent J,
Nicolau DP. Tissue pharmacokinetics of cefazolin in
patients with lower limb infections. Antimicrob
Agents Chemother. 2013;57(11):5679–83.
9. Stahle L, Arner P, Ungerstedt U. Drug distribution
studies with microdialysis III: extracellular
concentration of caffeine in adipose tissue in man.
Life Sci. 1991;49(24):1853–8.
278 Infect Dis Ther (2014) 3:269–279
10. Lipsky BA, Berendt AR, Cornia PB, et al. 2012
Infectious diseases society of America clinical
practice guideline for the diagnosis and treatment
of diabetic foot infections. Clin Infect Dis.
2012;54(12):132–73.
11. Chaurasia CS, Muller M, Bashaw ED, et al. AAPS-
FDA workshop white paper: microdialysis
principles, application, and regulatory
perspectives. J Clin Pharmacol. 2007;47(5):
589–603.
12. Dudley MN, Nightingale CH, Drezner AD, Low HB,
Wuintiliani R. Comparative penetration of
cefonicid and cefazolin into the atrial appendage
and pericardial fluid of patients undergoing open-
heart surgery. Antimicrob Agents Chemother.
1984;26(3):347–50.
13. Neely MN, van Guilder MG, Yamada WM,
Schumitzky A, Jelliffe RW. Accurate detection of
outliers and subpopulations with Pmetrics, a non-
parametric and parametric pharmacometric
modeling and simulation package for R. Ther
Drug Monit. 2012;34(4):467–76.
14. Yamaoka K, Nakagawa T, Uno T. Application of
Akaike’s information criterion (AIC) in the
evaluation of linear pharmacokinetic equations.
J Pharmacokinet Biopharm. 1978;6(2):165–75.
15. Cockcroft DW, Gault MH. Prediction of creatinine
clearance from serum creatinine. Nephron.
1976;16(1):31–41.
16. Winter MA, Guhr KN, Berg GM. Impact of various
body weights and serum creatinine concentrations
on the bias and accuracy of the Cockcroft–Gault
equation. Pharmacotherapy. 2012;32(7):604–12.
17. van Kralingen S, Taks M, Diepstraten J, et al.
Pharmacokinetics and protein binding of cefazolin
in morbidly obese patients. Eur J Clin Pharmacol.
2011;67(10):985–92.
18. Douglas A, Udy AA, Wallis SC, et al. Plasma and
tissue pharmacokinetics of cefazolin in patients
undergoing elective and semi-elective abdominal
aortic aneurysm open repair surgery. Antimicrob
Agents Chemother. 2011;55(11):5238–42.
19. Brill MJE, Houwink API, Schmidt S, et al. Reduced
subcutaneous tissue distribution of cefazolin in
morbidly obese versus non-obese patients
determined using clinical microdialysis.
J Antimicrob Chemother. 2014;69(3):715–23.
20. Muller M, dela Pena A, Derendorf H. Issues in
pharmacokinetics and pharmacodynamics of anti-
infective agents: distribution in tissue. Antimicrob
Agents Chemother. 2004;48(5):1441–53.
21. MacGowan AP, Bowker KE. Continuous infusion of
beta-lactam antibiotics. Clin Pharmacokinet. 1998;
35(5):391–402.
22. Craig WA. Pharmacokinetic/pharmacodynamic
parameters: rationale for antibacterial dosing of
mice and men. Clin Infect Dis. 1998;26(1):1–12.
23. Keel RA, Crandon JL, Nicolau DP. Efficacy of
human simulated exposures of ceftaroline
administered at 600 milligrams every 12 hours
against phenotypically diverse Staphylococcus
aureus isolates. Antimicrob Agents Chemother.
2011;55(9):4028–32.
24. Andes D, Craig WA. Pharmacodynamics of a new
cephalosporin, PPI-0903 (TAK-599), active against
methicillin-resistant Staphylococcus aureus in
murine thigh and lung infection models:
identification of an in vivo pharmacokinetic-
pharmacodynamic target. Antimicrob Agents
Chemother. 2006;50(4):1376–83.
25. Drusano GL. Antimicrobial pharmacodynamics:
critical interactions of ‘Bug and Drug’. Nat Rev
Microbiol. 2004;2(4):289–300.
26. Craig WA, Andes DR. In vivo pharmacodynamics of
ceftobiprole against multiple bacterial pathogens in
murine thigh and lung infection models.
Antimicrob Agents Chemother. 2008;52(10):
3492–6.
Infect Dis Ther (2014) 3:269–279 279
